ConverGene advances NCATS collaboration

ConverGene LLC (Cambridge, Md.) said it gained exclusive, worldwide rights from NIH's National Center for Advancing Translational Sciences to a portfolio of compounds targeting BET bromodomain proteins to treat or prevent mammalian diseases.

ConverGene originally conceived of the compounds' core structures in-house, Executive Director of Partnering and Strategy Elizabeth Smith told BioCentury. ConverGene and NCATS co-developed the portfolio under a Cooperative Research and Development Agreement (CRADA)...